

REMARKS

Applicant has amended claim 85 to clarify the wording for the method in which non-MAGE-A1 tumor antigen HLA class I or class II binding peptides are administered. No new matter has been added.

Respectfully submitted,

Luiten et al., Applicant



John R. Van Amsterdam, Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210
Telephone: (617) 720-3500

Docket No. L0461.70104US00

Date: August 28, 2003

xNDD